BBNX
Beta Bionics, Inc.
Price Chart
Latest Quote
$13.19
-0.76 (-5.45%)
Current Price
| Previous Close | $13.95 |
| Open | $14.01 |
| Day High | $14.24 |
| Day Low | $13.17 |
| Volume | 1,222,433 |
Stock Information
| Shares Outstanding | 44.56M |
| Total Debt | $6.91M |
| Cash Equivalents | $199.52M |
| Revenue | $110.24M |
| Net Income | $-66.44M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $587.77M |
| EPS (TTM) | $-1.37 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $429.03M |
| Sales | $110.24M |
| Income | $-66.44M |
| Book/sh | $6.09 |
| Cash/sh | $4.48 |
| Employees | 420 |
Financial Ratios
| Quick Ratio | 9.38 |
| Current Ratio | 10.69 |
| Debt/Eq | 2.55 |
Returns & Margins
| ROA | -15.04% |
| ROE | -22.71% |
| Gross Margin | 57.15% |
| Operating Margin | -87.86% |
| Profit Margin | -60.27% |
Ownership
| Insider Ownership | 1.10% |
| Institutional Ownership | 112.66% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -5.52 |
| P/S | 5.33 |
| P/B | 2.17 |
Analyst Data
| Recommendation | buy |
| Target Price | $19.18 |
Technical Indicators
| SMA20 | $12.93 |
| SMA50 | $11.53 |
| SMA200 | $18.49 |
| RSI | 58.83 |
| ATR | 0.9971 |
| Shares Float | 25.34M |
| Short Float | 11.73% |
| Short Ratio | 7.52 |
| Rel Volume | 1.29 |
Performance History
| Week | -3.86% |
| Month | +40.32% |
| Quarter | +24.08% |
| 6 Months | -55.62% |
| YTD | -54.91% |
| Year | -32.19% |
| 10 Years | -44.18% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $13.19 | 1,228,000 |
| 2026-06-16 | $13.95 | 1,124,300 |
| 2026-06-15 | $14.38 | 941,700 |
| 2026-06-12 | $14.53 | 1,328,600 |
| 2026-06-11 | $14.69 | 1,515,300 |
| 2026-06-10 | $13.72 | 712,600 |
| 2026-06-09 | $14.39 | 885,400 |
| 2026-06-08 | $13.87 | 1,263,500 |
| 2026-06-05 | $13.89 | 1,006,900 |
| 2026-06-04 | $13.89 | 1,323,800 |
| 2026-06-03 | $12.45 | 1,045,900 |
| 2026-06-02 | $12.79 | 900,400 |
| 2026-06-01 | $12.80 | 706,700 |
| 2026-05-29 | $12.12 | 430,300 |
| 2026-05-28 | $12.10 | 580,200 |
| 2026-05-27 | $11.63 | 572,800 |
| 2026-05-26 | $11.72 | 796,000 |
| 2026-05-22 | $11.82 | 1,128,200 |
| 2026-05-21 | $10.61 | 841,500 |
| 2026-05-20 | $10.11 | 660,100 |
| 2026-05-19 | $9.42 | 584,100 |
| 2026-05-18 | $9.40 | 964,700 |
About Beta Bionics, Inc.
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is headquartered in Irvine, California.
đ° Latest News
Beta Bionics to launch its first insulin patch pump to compete with Insulet
MedTech Dive âĸ 2026-05-26T10:15:49Z
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
Motley Fool âĸ 2026-05-15T22:50:53Z
Robert Bruce's Strategic Moves: A Closer Look at Beta Bionics Inc's Impactful Addition
GuruFocus.com âĸ 2026-05-14T21:05:12ZBeta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
MarketBeat âĸ 2026-05-13T06:05:50Z
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation
Simply Wall St. âĸ 2026-05-12T12:03:59Z
Beta Bionics, Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-04-22T12:30:00Z
Beta Bionics Inc (BBNX) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Operational ...
GuruFocus.com âĸ 2026-04-22T07:04:15ZBeta Bionics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-21T22:35:18Z
Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-04-21T21:15:02Z
Beta Bionics, Inc. (BBNX) Soars 10.3%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-04-16T07:47:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $44,714,000 | $29,236,000 | $5,687,000 | - |
| Cost Of Revenue | $44,714,000 | $29,236,000 | $5,687,000 | - |
| Total Revenue | $100,251,000 | $65,124,000 | $11,995,000 | $179,000 |
| Operating Revenue | $100,251,000 | $65,124,000 | $11,995,000 | $179,000 |
| Expenses | ||||
| Total Expenses | $171,932,000 | $110,375,000 | $47,845,000 | $66,023,000 |
| Other Income Expense | $-12,451,000 | $-13,414,000 | $-10,026,000 | $911,000 |
| Other Non Operating Income Expenses | $-1,000 | $-2,000 | $-68,000 | - |
| Net Non Operating Interest Income Expense | $10,932,000 | $3,909,000 | $1,777,000 | $182,000 |
| Operating Expense | $127,218,000 | $81,139,000 | $42,158,000 | $66,023,000 |
| Selling And Marketing Expense | $61,404,000 | $37,086,000 | $11,990,000 | $8,443,000 |
| General And Administrative Expense | $31,025,000 | $17,869,000 | $12,225,000 | $26,152,000 |
| Interest Expense | - | - | $68,000 | $14,000 |
| Interest Expense Non Operating | - | - | $68,000 | $14,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Net Interest Income | $10,932,000 | $3,909,000 | $1,777,000 | $182,000 |
| Interest Income | $10,932,000 | $3,909,000 | $1,777,000 | $196,000 |
| Normalized Income | $-60,750,000 | $-41,344,000 | $-34,141,000 | $-65,662,000 |
| Net Income From Continuing And Discontinued Operation | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Total Operating Income As Reported | $-71,681,000 | $-45,251,000 | $-35,850,000 | $-65,844,000 |
| Net Income Common Stockholders | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Net Income | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Net Income Including Noncontrolling Interests | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Net Income Continuous Operations | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Pretax Income | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Interest Income Non Operating | $10,932,000 | $3,909,000 | $1,777,000 | $196,000 |
| Operating Income | $-71,681,000 | $-45,251,000 | $-35,850,000 | $-65,844,000 |
| Gross Profit | $55,537,000 | $35,888,000 | $6,308,000 | $179,000 |
| Per Share | ||||
| Diluted EPS | $-1.81 | $-1.28 | $-1.45 | $-2.12 |
| Basic EPS | $-1.81 | $-1.28 | $-1.45 | $-2.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-56,356,000 | $-29,556,000 | $-23,801,000 | $-63,561,000 |
| Total Unusual Items | $-12,450,000 | $-13,412,000 | $-9,958,000 | $911,000 |
| Total Unusual Items Excluding Goodwill | $-12,450,000 | $-13,412,000 | $-9,958,000 | $911,000 |
| Reconciled Depreciation | $2,875,000 | $2,283,000 | $2,091,000 | $2,087,000 |
| EBITDA (Bullshit earnings) | $-68,806,000 | $-42,968,000 | $-33,759,000 | $-62,650,000 |
| EBIT | $-71,681,000 | $-45,251,000 | $-35,850,000 | $-64,737,000 |
| Diluted Average Shares | $40,529,051 | $42,859,341 | $30,495,423 | $30,495,423 |
| Basic Average Shares | $40,529,051 | $42,859,341 | $30,495,423 | $30,495,423 |
| Diluted NI Availto Com Stockholders | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Gain On Sale Of Security | $-12,450,000 | $-13,412,000 | $-9,958,000 | $911,000 |
| Research And Development | $34,789,000 | $26,184,000 | $17,943,000 | $31,428,000 |
| Selling General And Administration | $92,429,000 | $54,955,000 | $24,215,000 | $34,595,000 |
| Other Gand A | $31,025,000 | $17,869,000 | $12,225,000 | $21,606,000 |
| Salaries And Wages | - | - | $3,638,000 | $4,546,000 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $287,610,000 | $-245,360,000 | $-203,105,000 | $-170,034,000 |
| Total Assets | $328,743,000 | $149,645,000 | $110,040,000 | $35,527,000 |
| Total Non Current Assets | $60,838,000 | $16,722,000 | $6,419,000 | $7,060,000 |
| Other Non Current Assets | $180,000 | $250,000 | $221,000 | $193,000 |
| Non Current Deferred Assets | $0 | $5,051,000 | $0 | - |
| Investmentin Financial Assets | $45,431,000 | $0 | - | - |
| Current Assets | $267,905,000 | $132,923,000 | $103,621,000 | $28,467,000 |
| Restricted Cash | $100,000 | $0 | - | - |
| Prepaid Assets | $7,064,000 | $2,982,000 | $908,000 | $542,000 |
| Inventory | $21,722,000 | $13,320,000 | $1,245,000 | $0 |
| Receivables | $19,894,000 | $13,046,000 | $4,448,000 | $0 |
| Taxes Receivable | $265,000 | $817,000 | - | - |
| Accrued Interest Receivable | $2,511,000 | $233,000 | - | - |
| Accounts Receivable | $17,118,000 | $11,996,000 | $4,448,000 | $0 |
| Allowance For Doubtful Accounts Receivable | $-156,000 | $-116,000 | $-46,000 | - |
| Gross Accounts Receivable | $17,274,000 | $12,112,000 | $4,494,000 | - |
| Cash Cash Equivalents And Short Term Investments | $219,125,000 | $103,575,000 | $96,745,000 | $27,675,000 |
| Cash And Cash Equivalents | $31,576,000 | $30,432,000 | $26,566,000 | $27,675,000 |
| Other Current Assets | - | $1,050,000 | $275,000 | $250,000 |
| Debt | ||||
| Total Debt | $7,303,000 | $7,255,000 | $4,223,000 | $4,133,000 |
| Long Term Debt And Capital Lease Obligation | $5,365,000 | $5,726,000 | $2,999,000 | $3,157,000 |
| Current Debt And Capital Lease Obligation | $1,938,000 | $1,529,000 | $1,224,000 | $976,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $41,133,000 | $395,005,000 | $313,145,000 | $205,561,000 |
| Total Non Current Liabilities Net Minority Interest | $10,209,000 | $373,857,000 | $302,540,000 | $196,688,000 |
| Other Non Current Liabilities | $1,547,000 | - | - | - |
| Derivative Product Liabilities | $0 | $44,898,000 | $37,573,000 | $10,497,000 |
| Non Current Deferred Liabilities | $3,297,000 | $1,860,000 | $255,000 | $0 |
| Current Liabilities | $30,924,000 | $21,148,000 | $10,605,000 | $8,873,000 |
| Other Current Liabilities | $328,000 | $337,000 | $462,000 | $184,000 |
| Current Deferred Liabilities | $1,557,000 | $939,000 | $87,000 | $0 |
| Payables And Accrued Expenses | $12,838,000 | $7,744,000 | $3,357,000 | $2,332,000 |
| Payables | $4,998,000 | $2,852,000 | $1,166,000 | $1,570,000 |
| Accounts Payable | $4,998,000 | $2,852,000 | $1,166,000 | $430,000 |
| Equity | ||||
| Common Stock Equity | $287,610,000 | $-245,360,000 | $-203,105,000 | $-170,034,000 |
| Total Equity Gross Minority Interest | $287,610,000 | $-245,360,000 | $-203,105,000 | $-170,034,000 |
| Stockholders Equity | $287,610,000 | $-245,360,000 | $-203,105,000 | $-170,034,000 |
| Gains Losses Not Affecting Retained Earnings | $403,000 | $65,000 | $137,000 | $0 |
| Other Equity Adjustments | $403,000 | $65,000 | $137,000 | - |
| Retained Earnings | $-369,937,000 | $-296,737,000 | $-229,664,000 | $-185,565,000 |
| Preferred Securities Outside Stock Equity | $0 | $321,373,000 | $261,713,000 | $183,034,000 |
| Other | ||||
| Ordinary Shares Number | $44,360,873 | $42,859,341 | $42,859,341 | $42,859,341 |
| Share Issued | $44,360,873 | $42,859,341 | $42,859,341 | $42,859,341 |
| Tangible Book Value | $287,610,000 | $-245,360,000 | $-203,105,000 | $-170,034,000 |
| Invested Capital | $287,610,000 | $-245,360,000 | $-203,105,000 | $-170,034,000 |
| Working Capital | $236,981,000 | $111,775,000 | $93,016,000 | $19,594,000 |
| Capital Lease Obligations | $7,303,000 | $7,255,000 | $4,223,000 | $4,133,000 |
| Total Capitalization | $287,610,000 | $-245,360,000 | $-203,105,000 | $-170,034,000 |
| Additional Paid In Capital | $657,140,000 | $51,311,000 | $26,421,000 | $15,530,000 |
| Capital Stock | $4,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $4,000 | $1,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | - | - |
| Non Current Deferred Revenue | $3,297,000 | $1,860,000 | $255,000 | $0 |
| Long Term Capital Lease Obligation | $5,365,000 | $5,726,000 | $2,999,000 | $3,157,000 |
| Current Deferred Revenue | $1,557,000 | $939,000 | $87,000 | $0 |
| Current Capital Lease Obligation | $1,938,000 | $1,529,000 | $1,224,000 | $976,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,656,000 | $9,942,000 | $5,475,000 | $5,381,000 |
| Current Provisions | $1,607,000 | $657,000 | - | - |
| Current Accrued Expenses | $7,840,000 | $4,892,000 | $2,191,000 | $762,000 |
| Investments And Advances | $45,431,000 | $0 | - | - |
| Available For Sale Securities | $45,431,000 | - | - | - |
| Net PPE | $15,227,000 | $11,421,000 | $6,198,000 | $6,867,000 |
| Accumulated Depreciation | $-5,755,000 | $-5,253,000 | $-4,420,000 | $-3,374,000 |
| Gross PPE | $20,982,000 | $16,674,000 | $10,618,000 | $10,241,000 |
| Leases | $830,000 | $810,000 | $951,000 | $951,000 |
| Construction In Progress | $3,339,000 | $1,735,000 | $167,000 | $182,000 |
| Other Properties | $15,874,000 | $12,897,000 | $8,108,000 | $7,556,000 |
| Machinery Furniture Equipment | $939,000 | $1,232,000 | $1,392,000 | $1,552,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $10,416,000 | $5,946,000 | $408,000 | - |
| Work In Process | $2,750,000 | $637,000 | $34,000 | - |
| Raw Materials | $8,556,000 | $6,737,000 | $803,000 | - |
| Other Short Term Investments | $187,549,000 | $73,143,000 | $70,179,000 | $0 |
| Dueto Related Parties Current | - | - | $0 | $1,140,000 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-56,222,000 | $-51,668,000 | $-32,847,000 | $-60,980,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-50,925,000 | $-48,273,000 | $-32,445,000 | $-60,208,000 |
| Cash Flow From Continuing Operating Activities | $-50,925,000 | $-48,273,000 | $-32,445,000 | $-60,208,000 |
| Operating Gains Losses | $12,481,000 | $13,435,000 | $9,969,000 | $-868,000 |
| Investing Activities | ||||
| Capital Expenditure | $-5,297,000 | $-3,395,000 | $-402,000 | $-772,000 |
| Investing Cash Flow | $-162,805,000 | $-3,476,000 | $-69,693,000 | $-769,000 |
| Cash Flow From Continuing Investing Activities | $-162,805,000 | $-3,476,000 | $-69,693,000 | $-769,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $210,117,000 | $59,660,000 | $101,000,000 | $56,393,000 |
| Financing Cash Flow | $214,874,000 | $55,615,000 | $101,029,000 | $56,782,000 |
| Cash Flow From Continuing Financing Activities | $214,874,000 | $55,615,000 | $101,029,000 | $56,782,000 |
| Net Preferred Stock Issuance | $0 | $59,660,000 | $101,000,000 | $56,393,000 |
| Preferred Stock Issuance | $0 | $59,660,000 | $101,000,000 | $56,393,000 |
| Net Common Stock Issuance | $210,117,000 | $0 | - | - |
| Common Stock Issuance | $210,117,000 | $0 | - | - |
| Net Other Financing Charges | - | $-4,147,000 | - | - |
| Other | ||||
| End Cash Position | $31,676,000 | $30,532,000 | $26,666,000 | $27,775,000 |
| Beginning Cash Position | $30,532,000 | $26,666,000 | $27,775,000 | $31,970,000 |
| Changes In Cash | $1,144,000 | $3,866,000 | $-1,109,000 | $-4,195,000 |
| Proceeds From Stock Option Exercised | $4,757,000 | $102,000 | $29,000 | $389,000 |
| Net Investment Purchase And Sale | $-157,508,000 | $-131,000 | $-69,295,000 | $0 |
| Sale Of Investment | $170,000,000 | $72,000,000 | $0 | - |
| Purchase Of Investment | $-327,508,000 | $-72,131,000 | $-69,295,000 | $0 |
| Net PPE Purchase And Sale | $-5,297,000 | $-3,345,000 | $-398,000 | $-769,000 |
| Sale Of PPE | $0 | $50,000 | $4,000 | $3,000 |
| Purchase Of PPE | $-5,297,000 | $-3,395,000 | $-402,000 | $-772,000 |
| Change In Working Capital | $-8,992,000 | $-12,148,000 | $-5,305,000 | $-2,790,000 |
| Change In Other Working Capital | $2,055,000 | $2,457,000 | $342,000 | $-179,000 |
| Change In Other Current Liabilities | $311,000 | $-1,023,000 | $-2,088,000 | $-732,000 |
| Change In Other Current Assets | $-30,000 | $-29,000 | $-28,000 | $86,000 |
| Change In Payables And Accrued Expense | $9,522,000 | $8,353,000 | $2,541,000 | $-2,084,000 |
| Change In Accrued Expense | $7,424,000 | $6,838,000 | $1,825,000 | $-2,007,000 |
| Change In Payable | $2,098,000 | $1,515,000 | $716,000 | $-77,000 |
| Change In Account Payable | $2,098,000 | $1,515,000 | $716,000 | $-77,000 |
| Change In Prepaid Assets | $-5,808,000 | $-2,849,000 | $-391,000 | $119,000 |
| Change In Inventory | $-9,880,000 | $-11,439,000 | $-1,187,000 | $0 |
| Change In Receivables | $-5,162,000 | $-7,618,000 | $-4,494,000 | $0 |
| Changes In Account Receivables | $-5,162,000 | $-7,618,000 | $-4,494,000 | $0 |
| Other Non Cash Items | $-1,991,000 | - | - | $14,000 |
| Stock Based Compensation | $16,384,000 | $6,384,000 | $5,658,000 | $6,100,000 |
| Provisionand Write Offof Assets | $1,518,000 | $-566,000 | $-12,000 | $0 |
| Depreciation Amortization Depletion | $2,875,000 | $2,283,000 | $2,091,000 | $2,087,000 |
| Depreciation And Amortization | $2,875,000 | $2,283,000 | $2,091,000 | $2,087,000 |
| Depreciation | $2,875,000 | $2,283,000 | $2,091,000 | $2,087,000 |
| Gain Loss On Investment Securities | $12,450,000 | $13,412,000 | $9,958,000 | $-911,000 |
| Gain Loss On Sale Of PPE | $31,000 | $23,000 | $11,000 | $43,000 |
| Net Income From Continuing Operations | $-73,200,000 | $-54,756,000 | $-44,099,000 | $-64,751,000 |
| Amortization Of Securities | - | $-2,905,000 | $-747,000 | $0 |
Fetched: 2026-06-14